Cladribine (RWJ 26251)

For research use only. Not for use in humans.

目录号:S1199 别名: Leustatin, 2-CdA, 2-chlorodeoxyadenosine, 2-Chloro-2′-deoxyadenosine, CldAdo, Jk 6251, NSC 105014 中文名称:克拉利宾

Cladribine (RWJ 26251) Chemical Structure

CAS No. 4291-63-8

Cladribine (RWJ 26251, Leustatin, 2-CdA, 2-chlorodeoxyadenosine, 2-Chloro-2′-deoxyadenosine, CldAdo, Jk 6251, NSC 105014)是一种腺苷脱氨酶抑制剂,作用于U266, RPMI8226,和MM1.S细胞,IC50分别约为2.43 μM, 0.75 μM,和0.18 μM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 979.91 现货
RMB 792.01 现货
RMB 1382.86 现货
RMB 2432.43 现货
RMB 4013.1 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Cladribine (RWJ 26251)发表文献11篇:

产品安全说明书

Adenosine Deaminase抑制剂选择性比较

生物活性

产品描述 Cladribine (RWJ 26251, Leustatin, 2-CdA, 2-chlorodeoxyadenosine, 2-Chloro-2′-deoxyadenosine, CldAdo, Jk 6251, NSC 105014)是一种腺苷脱氨酶抑制剂,作用于U266, RPMI8226,和MM1.S细胞,IC50分别约为2.43 μM, 0.75 μM,和0.18 μM。
特性 Cladribine主要在淋巴组织中具有活性。
靶点
Adenosine deaminase (MM1.S cells) [1] Adenosine deaminase (RPMI8226 cells) [1] Adenosine deaminase (U266 cells) [1]
0.18 μM 0.75 μM 2.43 μM
体外研究

Cladribine对毛细胞白血病(HCL),一种慢性B淋巴细胞增生疾病发挥显著的活性,延长完全缓解期。Cladribine诱导DNA链断裂累积,随后激活淋巴细胞中抑癌基因p53。Cladribine可能调节MM细胞中STAT3活性。Cladribine剂量依赖性抑制U266,RPMI8226和MM1.S细胞的增殖/存活。其中U266对cladribine敏感性最低,而对MM1.S敏感性最高。Cladribine治疗逐渐增加细胞周期中G1期的细胞比例,并减少S期细胞。Cladribine处理24小时后似乎能够增加U266细胞中G2-M期的比例。在RPMI8226和MM1.S细胞中都能观察到cladribine诱导的细胞凋亡剂量依赖性增加。0.2 μM cladribine治疗时间依赖性显著诱导MM1.S 中caspase-3,-8,和-9激活和PARP裂解。Cladribine剂量依赖性显著降低磷酸STAT3 (P-STAT3)水平,但是不影响总STAT3蛋白质水平。[1] Cladribine在HSB2细胞中具有浓度依赖性诱导细胞凋亡的潜能。[2] Cladribine以剂量依赖的方式抑制原代肥大细胞(MC)和MC系HMC-1生长,含有KIT D816V的HMC-1.2细胞与KIT D816V缺失的HMC-1.1细胞相比,具有较低的IC50值。[3] Cladribine降低CD14+单核细胞,以及CD4+和CD8+ T淋巴细胞的迁移能力。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CCRF-CEM cell lines MUDDfZRwfG:6aXPpeJkh[XO|YYm= NF;HTHhEd22yb4Xu[EB4[XNidHXzeIVlKG[xcjDjfZRwfG:6aXPpeJkh[WejaX7zeEBES1KILVPFUUBk\WyuIHzpcoV{NCCLQ{WwQVAvODB|IN88US=> NHfrNG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OyOVU3Lz5zN{OyOVU3RC:jPh?=
HEp-2 cell lines NVPD[mZtS3m2b4TvfIlkcXS7IHHzd4F6 M{D2cGNwdXCxdX7kJJdieyC2ZYP0[YQh\m:{IHP5eI91d3irY3n0fUBi\2GrboP0JGhGeC1{IHPlcIwhdGmwZYOsJGlEPTB;MD6wN{DPxE1? M1vuZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{K1OVYoRjF5M{K1OVY9N2F-
L1210 cell lines NXnBdJNpS3m2b4TvfIlkcXS7IHHzd4F6 M3f4e2NwdXCxdX7kJJdieyC2ZYP0[YQh\m:{IHP5eI91d3irY3n0fUBi\2GrboP0JGwyOjFyIHPlcIwhdGmwZYOsJGlEPTB;MD6wO{DPpG1? MkmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|MkW1Okc,OTd|MkW1Olww[T5?
CCRF-CEM cells MVjDfZRwfG:6aXPpeJkh[XO|YYm= M4TrR|czKGh? NWnoU4hwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0OURj3DSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNFUh|ryP NIHPOZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi0NFczOid-MkG4OFA4OjJ:L3G+
human Raji cells NW[4dI56S3m2b4TvfIlkcXS7IHHzd4F6 M3TU[|czKGh? NFPUc|hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT[WqrIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODlizszN NV7GWIZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OFA4OjJpPkKxPFQxPzJ{PD;hQi=>
human HuH7 cells NV75bGNTS3m2b4TvfIlkcXS7IHHzd4F6 MkjKO|IhcA>? NWnac4IxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVEvQCEQvF2= MnSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkKyO|coRjJ3NE[yNlc4RC:jPh?=
human T47D cells NXfTdoZPS3m2b4TvfIlkcXS7IHHzd4F6 MmjCO|IhcA>? MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUOFdFKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD63JO69VQ>? M4rYT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlc4Lz5{NUS2NlI4PzxxYU6=
human HCT116 cells NV;USI5VS3m2b4TvfIlkcXS7IHHzd4F6 MYG3NkBp M1nPUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOyEQvF2= M1T1UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlc4Lz5{NUS2NlI4PzxxYU6=
human K562 cells M{nTVHBzd2yrZnXyZZRqd25iYYPzZZk> NX32blV[PDhiaB?= NIO5UGVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTFyIN88US=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEOyN{c,OjV7NkCzNlM9N2F-
human SKHEP1 cells Mk\tVJJwdGmoZYLheIlwdiCjc4PhfS=> NVrTZ5d5PDhiaB?= MmriRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVS1jFVFEh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTRizszN NGDKOnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NFMzOyd-MkW5OlA{OjN:L3G+
human MOLT3 cells MUDQdo9tcW[ncnH0bY9vKGG|c3H5 NXvrWI1NPDhiaB?= MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTGSzJINmdGy|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0zNjNizszN MnvWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCzNlMoRjJ3OU[wN|I{RC:jPh?=
human KG1 cells MYjQdo9tcW[ncnH0bY9vKGG|c3H5 Mm[zOFghcA>? NWnM[mk4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLS|Eh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMjFOwG0> NV;2PZBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlA{OjNpPkK1PVYxOzJ|PD;hQi=>
human RPMI8226 cells NY\XUVdbWHKxbHnm[ZJifGmxbjDhd5NigQ>? MnP2OFghcA>? NGXmNoJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLQUWk5OjJ4IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME22JO69VQ>? MmrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCzNlMoRjJ3OU[wN|I{RC:jPh?=
human MCF7 cells NUnjb|JmWHKxbHnm[ZJifGmxbjDhd5NigQ>? M2XIUFQ5KGh? M3LNZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PDVizszN MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEOyN{c,OjV7NkCzNlM9N2F-
human SK-UT-1B cells NG\3NWJRem:uaX\ldoF1cW:wIHHzd4F6 MlTVOFghcA>? M4\xVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utWXQuOUJiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGg{txO Ml\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCzNlMoRjJ3OU[wN|I{RC:jPh?=
L1210 cell lines M1nFb2Z2dmO2aX;uJIF{e2G7 NF3KPWpKdiC4aYTyc{BqdmirYnn0c5J6KGWoZnXjeEB4[XNidHXzeIVlKG[xcjDjfZRwe3SjdHnjJIFkfGm4aYT5JI9vKHSqZTDndo94fGhib3[gcZVzcW6nIHzleYtmdWmlIFyxNlExKGOnbHygcIlv\XNuIFnEOVA:OC5yMzFOwG0> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl3Nk[2K|4zQTl3Nk[2QE9iRg>?
P388 leukemic cell lines M2\0e2Z2dmO2aX;uJIF{e2G7 NHHUW4JKdiC4aYTyc{BqdmirYnn0c5J6KGWoZnXjeEB4[XNidHXzeIVlKG[xcjDjfZRwe3SjdHnjJIFkfGm4aYT5JI9vKHSqZTDndo94fGhib3[gcJlueGixaXSgcoVweGyjc32gVFM5QCCuZYXr[Y1q[yClZXzsJIxqdmW|LDDJSFUxRTBwMEOg{txO NXzMflZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OVY3Pid-Mkm5OVY3PjxxYU6=
BV173 M4LxdmN6fG:2b4jpZ4l1gSCjc4PhfS=> MorLN{Bl[Xm| M17GPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJXOTd|IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODB6zszN MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
BT549 MVrDfZRwfG:6aXPpeJkh[XO|YYm= M1TrelMh\GG7cx?= MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCWFU1QSClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNVI{|ryP NEPQdoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
CT26 NF;BZ2JEgXSxdH;4bYNqfHliYYPzZZk> M{\nOlMh\GG7cx?= MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDDWFI3KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xN|HPxE1? MnfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
MES-SA NYrHVFJMS3m2b4TvfIlkcXS7IHHzd4F6 M4jQRVMh\GG7cx?= NXjrR4d6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBJINmdGy|IHHmeIVzKDNiZHH5d{BjgSCPVGSgZZN{[XluIFnDOVA:OC5zNkZOwG0> NWXUWpZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO|EyODV2PD;hQi=>
K562 MWXDfZRwfG:6aXPpeJkh[XO|YYm= NX7ndmdyOyCmYYnz NV\kRnFMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4heGGlbHn0ZZhmdCC{ZYPpd5RidnRiS{W2NkBk\WyuczDh[pRmeiB|IHThfZMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMUhOwG0> M1n5ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
P388D1 NGWwc|NEgXSxdH;4bYNqfHliYYPzZZk> NWXwNIM5OyCmYYnz MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDQN|g5TDFiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlI5Pc7:TR?= M4LVb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
CEM-DNR-bulk NW\wT|Q5S3m2b4TvfIlkcXS7IHHzd4F6 M3H0O|Mh\GG7cx?= M{TvfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVS2GTmKtZpVtcyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuN|Uz|ryP MnzyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
L1210 NFPtR4dEgXSxdH;4bYNqfHliYYPzZZk> NFTMWmM{KGSjeYO= NFfkNoJEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNOTJzMDDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOzl|zszN Mn2yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
EL4 MmraR5l1d3SxeHnjbZR6KGG|c3H5 MlvxN{Bl[Xm| M3KyUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGVNPCClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuPFQ5|ryP NFn0UZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
MCF7 M2nvemN6fG:2b4jpZ4l1gSCjc4PhfS=> MWWzJIRigXN? M1vRVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2yMlM2|ryP M1[4S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
K562 MV3DfZRwfG:6aXPpeJkh[XO|YYm= M3fDNFMh\GG7cx?= Mnn2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUeuOlnPxE1? NHXP[3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
PC3 NVvwV3h3S3m2b4TvfIlkcXS7IHHzd4F6 NUPoU|hpOyCmYYnz MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IF3UWEBie3OjeTygTWM2OD16LkK4{txO M1XiT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
C6 NHv4NWxEgXSxdH;4bYNqfHliYYPzZZk> M{CzWVMh\GG7cx?= NWnke|lOS3m2b4TvfIlkcXS7IHHnZYlve3RicnH0JGM3KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;OT6wO:69VQ>? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
HPAC MlLkR5l1d3SxeHnjbZR6KGG|c3H5 M4fzXVMh\GG7cx?= NXLUWZBGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFCDQzDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVkvOzMQvF2= NEKySW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
HCT116 NFXXdFhEgXSxdH;4bYNqfHliYYPzZZk> M3fOcVMh\GG7cx?= M{\OOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVkvPDQQvF2= NGn5e4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
HT-29 NWK2[HM4S3m2b4TvfIlkcXS7IHHzd4F6 NUL4PJBiOyCmYYnz M3v3bGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9PU41PM7:TR?= M2jxclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
HCT116 NXLGb3ZlS3m2b4TvfIlkcXS7IHHzd4F6 Ml3LO|IhcHK| NWTZc3oyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6z{txO NVnrZ2t7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNVkxPDZpPkK4NlE6ODR4PD;hQi=>
HuH7 NYCz[|N4S3m2b4TvfIlkcXS7IHHzd4F6 NX\3NVJ3PzJiaILz NXzlcphjS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTFwON88US=> M4fQVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkG5NFQ3Lz5{OEKxPVA1PjxxYU6=
MCF7 NWXnOG96S3m2b4TvfIlkcXS7IHHzd4F6 MYO3NkBpenN? MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9Nu69VQ>? M4flNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkG5NFQ3Lz5{OEKxPVA1PjxxYU6=
TC32 M2joUZFJXFNiYYPzZZk> MmLCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 NGT1ToVyUFSVIHHzd4F6 NH\xNHhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NYjHNlY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 NFz6e2VyUFSVIHHzd4F6 M1TDSJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NFHmTIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NXHDRmp{eUiWUzDhd5NigQ>? NVjIVlNoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NE\uWYhyUFSVIHHzd4F6 MU\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? NIHGfXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 M1zhNJFJXFNiYYPzZZk> MkCwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 NIeyZ2ZyUFSVIHHzd4F6 NV\OW2F7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz NIe1emY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 NX;ySVN6eUiWUzDhd5NigQ>? M4PhS5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= MmTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) NIjF[mxyUFSVIHHzd4F6 MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NILidpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 NHTTT4hyUFSVIHHzd4F6 NYnuZ2tSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 Ml\NdWhVWyCjc4PhfS=> NH;U[ZZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? MlfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC MVfxTHRUKGG|c3H5 MmfMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>? M2W0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 M1Xoe5FJXFNiYYPzZZk> MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0{PyClZXzsdy=> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 MYfxTHRUKGG|c3H5 MkTsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=> NVK5e2FyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) M3\kfZFJXFNiYYPzZZk> NIqxNIZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>? M{[wW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

体内研究 Cladribine (0.7-3.5 mM)和/或diltiazem (2.4 mM),腹腔注射到成年斑马鱼,通过HPLC分析心血管健康的潜在标志物,红血球(RBC)裂解物嘌呤核苷酸(例如ATP)的水平。Diltiazem增加RBC ATP浓度,该作用被共注射cladribine所抑制。[5] Ia 和s.c.给药后,伴随双相下降,Cladribine血浆浓度急速减少。单剂Cladribine 以1 mg/kg ia 和 2 mg/kg s.c. 注射后,AUC和t 1/2β分别为0.66: 1.2 μg ×h/mL和3.5: 4.5小时。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: U266,RPMI8226 和 MM1.S
  • Concentrations: 0 μM - 32 μM
  • Incubation Time: 72小时
  • Method: 非放射性细胞增殖试剂盒用于测定细胞活性。简而言之,人MM细胞系U266,RPMI8226和MM1.S接种到96孔板,0.1 mL完全培养基(5% FBS)为对照组,0.1 mL包含一系列剂量cladribine的相同培养基为试验组,培养72小时。使用微板读书器在490 nm下读取所有孔中的细胞数量,每组相对于100%存活率对照组的存活细胞百分数,通过MTS的减少测定。
    (Only for Reference)
动物实验:[5]
- 合并
  • Animal Models: 成年野生型(AB)斑马鱼
  • Dosages: 0.7 mM - 3.5 mM
  • Administration: 腹腔注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 57 mg/mL (199.51 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+1% Tween 80+H2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 285.69
化学式

C10H12ClN5O3

CAS号 4291-63-8
储存条件 粉状
溶于溶剂
别名 Leustatin, 2-CdA, 2-chlorodeoxyadenosine, 2-Chloro-2′-deoxyadenosine, CldAdo, Jk 6251, NSC 105014

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04997148 Recruiting -- Relapsing-Remitting Multiple Sclerosis Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany|Merck Serono Limited an affiliate of Merck KGaA Darmstadt Germany August 11 2021 --
NCT04821596 Recruiting Other: biological collection Multiple Sclerosis University Hospital Rouen July 13 2020 Not Applicable
NCT04121065 Not yet recruiting Procedure: Blood withdrawal Relapsing Multiple Sclerosis Neuromed IRCCS January 2020 --
NCT04934800 Recruiting Drug: Cladribine Multiple Sclerosis Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany|Merck Hellas sa. Greece December 10 2019 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂
Tags: 购买Cladribine (RWJ 26251) | Cladribine (RWJ 26251)供应商 | 采购Cladribine (RWJ 26251) | Cladribine (RWJ 26251)价格 | Cladribine (RWJ 26251)生产 | 订购Cladribine (RWJ 26251) | Cladribine (RWJ 26251)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID